Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CANC will - over the next 2 Weeks and hit - by . In that time frame, CANC's share price is expected to range between - and -.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No Data | |||||||||||||||||||
CANC shares fell -1.78% in Thursday, September 10, 2026's trading session, dropping from a previous close of $42.52 to move at $41.76. The stock demonstrated notable intraday movement (see CANC's key stats for a full breakdown), fluctuating between $41.69 and $42.34, a +1.56% trading range. While recent weeks have seen some volatility, CANC has managed to secure a -6.76% drop over the past 2 weeks. The downward price movement was accompanied by increased trading volume, with approximately 32.23K shares changing hands, 9.14K more than the previous session. This amounted to $1.35M in total market activity.
Will CANC Continue Its Trend?
According to analyst ratings and projections for CANC, Tema Oncology ETF shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators currently suggest a bearish sentiment for CANC. However, the stock has recorded 16 positive trading days within the past 30 sessions. Based on the CANC stock forecast, now is not the best time to buy CANC stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on CANC covering social and institutional perspectives.
CANC Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CANC's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 31.60% to 45.27%) suggest weak bearish momentum with possible fluctuation. The 50-day RSI, at 52.36%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 54.27%, maintains a neutral outlook for the long term. Insights into CANC's shareholder base show how institutional investors are positioning themselves during these momentum shifts

